Kouki Hoshino

Dr. Kouki Hoshino

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
MTMariko Tsukagoshi
Mariko Tsukagoshi
KAKenichiro Araki
Kenichiro Araki
TITakamichi Igarashi
Takamichi Igarashi
NINorihiro Ishii
Norihiro Ishii
SKShunsuke Kawai
Shunsuke Kawai
KSKen Shirabe
Ken Shirabe
Increasing evidence suggests that nutritional indices, including the geriatric nutritional risk index (GNRI) and prognostic nutritional index (PNI), are predictors of poor prognosis in patients with hepatocellular carcinoma (HCC). Hence, this study aimed to explore the value of the GNRI and PNI in evaluating postoperative prognosis in patients with HCC, particularly regarding its recurrence patterns. We performed a retrospective analysis of 203 patients with HCC who underwent initial hepatic resection. Patients were divided into two groups according to the GNRI (cutoff: 98) and PNI (cutoff: 45). The GNRI and PNI were significantly associated with body composition (body mass index and skeletal muscle mass index), hepatic function (Child-Pugh Score), tumor factors (tumor size and microvascular invasion), and perioperative factors (blood loss and postoperative hospitalization). Patients with a low PNI or low GNRI had significantly worse overall survival (OS) and recurrence-free survival. Patients with early recurrence had lower PNI and GNRI scores than those without early recurrence. Patients with extrahepatic recurrence had lower PNI and GNRI scores than those without extrahepatic recurrence. The PNI and GNRI might be useful in predicting the prognosis and recurrence patterns of patients with HCC after hepatic resection.

1 September 2019 in Pancreatology
Verified
Journal Article
Closed access
NHNorifumi Harimoto
Norifumi Harimoto
KHKouki Hoshino
Kouki Hoshino
RMRyo Muranushi
Ryo Muranushi
KHKei Hagiwara
Kei Hagiwara
TYTakahiro Yamanaka
Takahiro Yamanaka
KSKen Shirabe
Ken Shirabe

15 March 2021 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
TYTakahiro Yamanaka
Takahiro Yamanaka
NHNorifumi Harimoto
Norifumi Harimoto
Takehiko YokoboriTakehiko Yokobori
Takehiko Yokobori
RMRyo Muranushi
Ryo Muranushi
KHKouki Hoshino
Kouki Hoshino
KSKen Shirabe
Ken Shirabe
Treatment of hepatocellular carcinoma (HCC) is currently challenging. Cancer-associated fibroblasts (CAFs) promote the malignancy of HCC cells via production of cytokines. Conophylline (CnP), a vinca alkaloid obtained from Ervatamia microphylla leaves, has been reported to suppress activation of hepatic stellate cells and liver fibrosis in rats. We examined the efficacy of CnP in suppressing tumor growth in HCC. Specifically, we investigated whether CnP could inhibit CAFs, which were derived from HCC tissues in vitro and in vivo. Same as previous reports, CAFs promoted proliferative and invasive ability of HCC cells. CnP suppressed α-smooth muscle actin expression of CAFs, and inhibited their cancer-promoting effects. CnP significantly suppressed CAFs producting cytokines such as IL6, IL8, C-C motif chemokine ligand 2, angiogenin, and osteopontin (OPN). Combined therapy with sorafenib and CnP against HCC cells and CAFs in vivo showed to inhibit tumor growth the most compared with controls and single treatment with CnP or sorafenib. Transcriptome analysis revealed that GPR68 in CAFs was strongly suppressed by CnP. The cancer-promoting effects of cytokines were eliminated by knockdown of GPR68 in CAFs. CnP inhibited the HCC-promoting effects of CAFs by suppressing several HCC-promoting cytokines secreted by CAFs expressing GPR68. Combination therapy with CnP and existing anticancer agents may be a promising strategy for treating refractory HCC associated with activated CAFs.

1 March 2019 in Molecular Immunology
Verified
Journal Article
Closed access
TYToshiki Yajima
Toshiki Yajima
KHKouki Hoshino
Kouki Hoshino
RMRyo Muranushi
Ryo Muranushi
AMAkira Mogi
Akira Mogi
RORyoichi Onozato
Ryoichi Onozato
HKHiroyuki Kuwano
Hiroyuki Kuwano

15 August 2021 in Cancers
Verified
Journal Article
Open access
PDF file
MTMariko Tsukagoshi
Mariko Tsukagoshi
NHNorifumi Harimoto
Norifumi Harimoto
KAKenichiro Araki
Kenichiro Araki
NKNorio Kubo
Norio Kubo
AWAkira Watanabe
Akira Watanabe
KSKen Shirabe
Ken Shirabe
The efficacy and prognosis of adjuvant chemotherapy for resected pancreatic cancer remain unclear. We investigated the utility and risk factors of S-1 adjuvant chemotherapy in patients with pancreatic cancer undergoing pancreatectomy. This study comprised 80 patients, including 58 patients who received S-1 adjuvant chemotherapy. Skeletal muscle loss was defined using cutoff values of skeletal muscle mass index. In total, 16 (20%) octogenarian patients underwent pancreatectomy. Skeletal muscle loss was present in 56 (70%) patients. The entire course of S-1 adjuvant chemotherapy for 6 months was completed in 33 patients (41%). S-1 adjuvant chemotherapy <6 months was an independent prognostic indicator of poor overall survival. Patients who completed S-1 adjuvant chemotherapy exhibited significantly longer overall and relapse-free survival rates than those did not complete the chemotherapy (p < 0.0001 and p = 0.0003, respectively). Being an octogenarian and skeletal muscle loss were independent variables associated with the discontinuation of S-1 adjuvant chemotherapy. Finally, the S-1 adjuvant chemotherapy rates were 6.3% (1/16) and 28.6% (16/56) in octogenarian patients and those with skeletal muscle loss, respectively. S-1 adjuvant chemotherapy completion was associated with improved prognosis in patients with pancreatic cancer. Skeletal muscle loss and octogenarian status predicted the failure of S-1 adjuvant chemotherapy completion.

10 November 2021 in Hepatology Research
Verified
Journal Article
Closed access
PDF file
NHNorifumi Harimoto
Norifumi Harimoto
KAKenichiro Araki
Kenichiro Araki
RMRyo Muranushi
Ryo Muranushi
KHKouki Hoshino
Kouki Hoshino
TYTakahiro Yamanaka
Takahiro Yamanaka
KSKen Shirabe
Ken Shirabe